This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

I wouldn't be surprised to see a placement here. There is only 45mil shares in issue and if institutions do get on board there would be a shortage, it might take the volitity out. Dilution of course.

MS

I do not usually post on here but I see I sometimes get copied onto here so perhaps I should visit from time to time.
It seems that there is a bit of an air of disappointment from some on here which I do not share at all.

So, to counter that view, I am putting a copy of my earlier post on the Michael Walters site. Here goes.


It seems a few people had difficulty picking up the R&D presentation. You will still be able to watch it at any time later, if you can get it working, but you will need a broadband connection and Real player, I guess.

First reactions are that it was very impressive indeed.

Ruthenium sounds as if it will be sensational to me and likely to supersede the current platinum products which, before they came off patent, were a $5 billion a year market and growing.

Genvax appears to be still a fairly long way from hitting the market with a comercial product. So I am still mega bullish on MMG but, for me, Oncosense has moved massively up the scale but Genvax, perhaps just back a little. On the other hand, the news on Genvax/ prostate looked very encouraging with a very commercial product perhaps within reach.
But Ruthenium, wow.

I suppose that early price reaction will have been due to there being no announcement yet on clinical trials for ruthenium compounds. David Best explained it this way.
Ruthenium compounds can be 4 to 15 times more effective than platinum.
Resistance which the body can develop with platinum can be completely designed out in the ruthenium ones.
Toxicity of the best ruthenium molecules is extremely low.

Mr Best said that they could easily have been in clinical trials by now with a very effective ruthenium product but they have taken the view that, to maximise the attraction to big pharma, a little extra work could tweak the best molecules slightly to get an even better product and maximise the potential return. They will take three ruthenium compounds to trials later this year, he confirmed.

Best explained that they were originally intending to run trials on two compounds and they always target the safest ones first as safety is the top priority. However, early tests have shown them to have even lower toxicity than their best expectations so the decision has been made to also include a third compound which is super-effective but with a slightly higher toxicity.

I had not heard David Best before today but I must say that I thought that he came over very well. I am certainly gripping onto my shares after what I have heard today and the initial price drop does not concern me at all.

Xylos

cheers for the vote of confidence Xylos

Xylos I read your posts elsewhere and have enjoyed reading them. In fact I usually cut & paste them here for others to read. Your views well balanced and are most welcome. Definitely a cut above the others from the other place.

MS

Lads no harm meant but you are staring down the barrel of a sub 1 share

Its going to happen soon 20/30m would be more than a fair market cap for a company that makes no money and employes 12 people

Thats about 45/60p

Xylos I take it your from across the road please feel free to join us here. We are a freindly bunch and we indulge in constructive debate wether we agree with one another or not.

I like your summing up of the peresentation and agree with everything you say and I had forgotten about how D Best had mentioned the Prostate Genvax was near to commercialisation, so hopefully we should have some news flow pretty quickly from that.

What does annoy me though about this company is the PR side of things, ok some will say well at least they put on a web cast for retail investors and not many do that, fair enough but I still feel D Best shot himself in the foot today by going forward with a web cast when he knew that the Ruthenium trials had taken a step back (even though for quality and commercial reasons)and a lot of short term investors were expecting a positive announcement.

I also feel the company should have moved a lot quicker over the duff analyst report.

Having said that I am full of confidence for the future having had a few hours break cursing over the price this afternoon (and lets face it there were more buys than sells today)as I was expecting a big pay day later this week or next, but as they say its not gone away its just on hold for the time being. Bring on Vane Minerals.

cheers GF.

For those who missed it earlier.............



and




cheers GF.

Very Bullish around the boards tonight on this one. People talking about the chances of an early RNS on the prostrate Genvax and also how the lecture was really structured towards analysts from Brokers and Instituions with BUYS promised already.

cheers GF.

Why the huge drop yesterday?

A combination of short term traders expecting news on Ruthenium trials plus MM over indulgence. Buys were in fact just ahead of sells but we still got the drop.

cheers GF.

On the graph showing the pipeline. Can you put a time between the different phases.

MS

Not sure what you mean Mickey?. I just lifted it very quickly whilst the webcast was on.

cheers GF. PS, looks like another downer all over. Time to get back to value shares I reckon. More research required but the momentum market as now gone. Its hard trying to find anything that is cheap at the moment. Im going to spend the next two days on the 'digital look' stock screener and try and lever some value shares out.

Hi GF

You seem a little pessimistic at the moment. Do you think there is any significant rises left in MMG or have we seen the best of it for a while?

As a holder of these, thanks to everyone who has contributed to this thread as it's been a fascinating and informative read.

GF

I was wondering how long it takes for these drugs to pass through their various trial periods, ie from phase 1 to phase 2 etc. I'm trying to get a time frame in my mind as to when they will get to a point in development where they become of interest to others. In other words how long is my investment going to take to mature and do I have the patience to wait.

MS

Hello

GF - you mentioned yesterday that Mr Best shot himself int he foot by going forward with the presentation, implying maybe he should have delayed until the had a firmer position on the Ruthenuim trials ...

IMO this company sp suffers enough from a lack of news, and I think if the presentation had been delayed the we would have seen a sp drop anyway.

So, on a positive note, some news at least offers reassurance to those of us still clinging onto a glimmer of hope - which is better than no news at all!

Cheers
ffw

A bit down on the market Mark in general, perhaphs we might see better things after the General Election. As for MMG Im still very bullish and hold 7 tranches in profit going all the way back into the 40s and hold 3 tranches out of profit the highest being held at 211.5p. Id hold onto them as I expect institutional upgrades very soon, indeed we might get one from Killik today or perhaphs tomorrow. I will post it if and when it comes.

Mickey I cant say exactly how long it takes the drugs to go from one phase to another thats far too complex and depends on the drug itself, what I can say though that D Best CEO said the company would have 10 drugs in trials by the end of the year and the Genevax prostrate trial is very near commercialisation so we should have news pretty quickly on that.

Last night around 2 in the morning after doing my normal nightly research I needed to make sure I had got the story right on this one after the days events and the big fall in share price, I wondered were Evil K and the Bears right and I wrong?. So I had a further look at the free Mike Walters article which I reproduce below and which the Bear argument is centered around especially the Bearish Analyst report.

After reading it again I am absolutley sure I am right in being positive on this one and I ask you guys to have a re - read especially in the light of what we now know after the positives from yesterdays web cast, please take a very close look at the parts I have highlighted those which Mike points out are flawed by the 'now gone analyst'. I look upon the Bear case as being one centered upon total ignorance and missunderstanding of MMIs Technical Business Plan and can only think that those selling out are doing so because of financial need based on credit facility tightening.

Heres Mike Walters article what do you think now after yesterdays web cast?????????????????????????????????????????????????????.

Waandering Star
11/4/2005 (119264)

Waandering Star

Has our Gazza retired hurt, limping off to the quack with a fractured forelock after bashing his brains against Medical Marketing International (MMG)?

Who can say? In the nasty netherworld of stock bashers, bullies and shorters, we rarely see more than a shadow of the truth, glimpsing just a fleeting fragment of what is really happening as it flashes behind the backs of the massed regulators in their gilded docklands towers.

Forgive me this indulgent opening. But there will be many ready to join in a satisfied chuckle at speculation that KBC Peel Hunt analyst Gary Waanders might be leaving the firm. The stories come in the wake of two extraordinary reports which served to provide cart loads of ammunition for those who could not countenance the remarkable recent rise in MMGs shares from 80p or so to touch 300p a couple of weeks ago.

Gaz got it wrong in the eyes of many, drastically wrong. It was clear from the very beginning that he had not spoken to the company, and there were errors galore in it. It was also obvious that this was fodder for the usual wrecking crew to join him in assaulting the share price (see my bulletin board comment That Peel Hunt note on March 25). Time and again on our board, I warned that the note carried many errors and should not be taken too seriously (see Factual errors and false markets on the board April I).

Because of pressure of work, the complex nature of the science, and my reluctance to give greater publicity for something so far out of whack, I have been slow to talk about it in detail. The regulators discourage the circulation of many broker research notes to private investors, so the actual reports have not been published on the internet. Most have had simply to rely on assertions by the shorters that Waanders did a good job in estimating that the shares were worth 40p or less.

That is arrant nonsense, of course. Claims from the shorters that Waanders had produced a smashing or excellent sell note, with comments written in a balanced and reasoned manner were always outrageous. They came from sources who appear never to have raised the matter with the company and were ill-equipped to make any such judgement, relying only on a greedy gallop to damage the share price.

It was always astonishing that someone from a house like KBC Peel Hunt should produce a savage attack without first discussing the complex science with the company. Quite why any analyst should produce such a report out of the blue is unclear. On the face of it, anyone judging the value of MMGs research so scathingly must have sent a shudder through other research-based businesses where KBC Peel Hunt is broker.

Once the shock of the initial report was in the market, touted to all and sundry on the internet by shorter Evil Knievil and his tip sheet cronies, it was still more of a surprise that Waanders did not reconsider. Instead, after meeting the company and discussing his first note, he effectively retracted many of his key negatives not by owning up, but by re-stating his position without withdrawing his extraordinarily low valuation.

Closer analysis, though, makes it clear that he recognised that much of the ground on which he had based his original attack had shifted from beneath his feet. Indeed, anyone reading the second note, dated April 7, might almost conclude from his text that he was about the recommend the shares.

It is worth dealing with a few particulars, bearing in mind that the first March 24 (Waanders One) version was one and a half pages long, while the follow-up (Waanders Revised) spans nearly five pages.

Look first at Genvax, where Dr Freda Stevenson and the team at the University of Southampton appear to have achieved a breakthrough in developing DNA vaccines in the treatment of cancer.

Waanders One (W1) talks about some cause for concern regarding commercial development, and goes on to raise queries about intellectual property and such. W1 moves from may well be patentable but significant prior art exists in a number of closely related fields to confident that the company will be able to protect and defend its IP in Waanders Revised (WR).

In W1, he appears to confuse ownership of patents for delivering the vaccine (Vical has one) with ownership of patents for the vaccine. He suggests in W1 that technology rights have been licensed by the likes of Merck, Pfizer and others and in WR acknowledges that there would be no problem for Genvax we would not expect MMG to have any difficulty in obtaining a licence and we do not believe the terms of such a licence would be onerous. That effectively says that there should be no great obstacle to commercial viability on the IP front, and that obtaining the necessary licence is not an obstacle to raising value.

In W1, he implies that MMG may be hiding something, asking assuming the results and the potential were so significant, why has MMI not invited analysts to a presentation? In WR, he climbs down the company has, correctly, deferred full publication of the trial results to those organisations (the cancer charities which financed the research).

W1 suggests the market is small. WR changes tack, admitting the main commercial focuswill be the development of vaccines for broader cancer application such a prostate cancer or gastrointestinal cancers (stomach and colon) In fact, these cancers represent huge markets with massive unmet needs so the original statement was wrong. He admits as much in WR, saying Gastrointestinal cancers and prostate cancer, by virtue of the number of cases, represent much more significant potential market opportunities.

Attempt W1 looks at certain vaccine types and says from a commercial product point of views and manufacturing, this is a nightmare. In WR, he backs down, talking of the potential size of the market and potential manufacturing issues facing these bespoke vaccines, which we have learnt, are not insurmountable.

In W1, he mentions CEA carcino-embryonic antigen and dismisses the Genvax research, saying there is plenty of prior art on the antigen and its use in a cancer vaccine would effectively queer the commercialisation pitch. In WR, he crawls out of the wreckage, muttering This body of knowledge should not be considered negative because the company should still be able to obtain protection for its IP concerning the specific fusion protein combination of CESA with tetanus toxoid fragment.

He goes on in W1 to suggest that the vaccine platform holds little commercial value due to prior art concerns and market strategy This conclusion appears to be rendered invalid in his WR follow-up.

Looking at his assessment in W1 of Oncosense, the company which is developing ruthenium compounds as a possible treatment for cancer, along with a pineapple extract, he initially talks about Early development stage. After talking to the company, in WR he realises that it is much further advanced, and says The company has selected three compounds.

He suggests in W1 that it will be probably 1 year before clinical trials could be started. In WR, he admits they could proceed into Phase I/II this yearearlier thanwe had expected. He also talks of development hurdles which will be substantial given the more stringent regulatory regimes in place today, then in WR admits MMG has been advised that it only needs to complete short (2 week) toxicity studiesbefore it can proceed in human clinical studies. He also in WR talks about a conventional path through clinical development that should not be more onerous.

In W1, he talks about competing against drugs which are effectively generic and where substantial competition exists in the market, while in WR he backs down, and talks about targeting cancers where current treatment options are limited or non-existent, notably lung cancers an obviously large market opportunity.

I apologise if this is too detailed, and might sometimes seem to be splitting hairs. It is obvious that those who wish to denigrate the company can wave all such things away as fine, irrelevant detail. Anyone, though, who wraps a towel around their head and sits down to compare Waanders One with Waanders Revised will be aware there are substantial differences in the comment.
They might wonder why, in the light of new facts revealed to him by actually talking to the company, he has not revised his niggardly assessment of share value, something which continues to play into the hands of his apparently blindly devoted chorus of sceptics and short sellers.

It is right for all to acknowledge that setting valuations of such companies is notoriously difficult. Time and again I have warned of that. Most drugs do fail in the course of development, and some fail even after getting to market. So it is possible to take a totally negative view, and prove correct.

Normally, though, the market weights probabilities and possibilities. Other analysts who have looked at Medical Marketing have come to more optimistic valuations than Waanders. He is entitled to his opinion, and we are all entitled to wonder whether he is still working as an analyst at KBC Peel Hunt and if not, why not.

Toodle-pip!

I hold shares in Medical Marketing.

Ends

cheers GF.

GF - ok - so when do you sleep ? 'cos I can vouch that you are on the boards most mornings and also late at night.

B

All round temperamental small cap market at the mo could be something to do with the articles that have been popping up saying that the AIM is overvalued and the great run that small caps have had is coming to an end. Still, this is only an opinion. ???

Hi Baza, I run my business during the night, Large Industrial Cleaning (we have to be there when all others arent there if you know what I mean)and on quite periods do a bit of research etc in the office. Im off to bed now. I would appreciate your thoughts on my post above.

cheers GF. Ps, chad Im certain you are right and thats why we need to move from momentum stocks to sound fundy stocks with sound asset backing. The tech blue skyers have had it now for a while, its back to the boring. Sees ya later.